Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Account Payables
Amounts the company owes suppliers for goods and services received.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 55.3% from a year ago
Account payables stood at $8.94M at the end of Q1 FY2026, down 55.3% from a year earlier and up 25.8% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.
Context
- Account payables amounted to 1.2% of total assets at the end of Q1 FY2026, down 4.8 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -55.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 7.11M USD
- Year-over-year change
- -58.5%
- 3-year CAGR
- +6.9%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.11M | -58.5% |
| FY2024 | 2024-12-31 | 17.14M | +217.6% |
| FY2023 | 2023-12-31 | 5.4M | -7.2% |
| FY2022 | 2022-12-31 | 5.82M | — |
Account Payables vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 account payables of $8.94M is the 3rd highest of the 8 companies compared; the peer median is $7.17M.
- Its year-over-year change of -55.3% is the 5th highest of 7, against a peer median of +13.3%.
- Account payables amounts to 1.2% of total assets for ZBIO, versus a peer median of 2.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $17.53M | +68.0% | +26.3% | 6.7% | |
| Mar 2026 | $14.73M | +131.8% | +8.3% | 7.4% | |
| Mar 2026 | $8.94M | -55.3% | +6.9% | 1.2% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $7.5M | — | — | 2.6% |
| Dec 2025 | $7.17M | +28.5% | +13.1% | 62.4% | |
| Sep 2026 | $6.79M | -1.9% | +77.3% | 0.9% | |
UPBUpstream Bio, Inc. | Mar 2026 | $1.71M | -63.8% | +56.4% | 0.5% |
| Mar 2026 | $653K | -75.9% | -15.1% | 1.0% | |
| Peer median (excluding ZBIO) | $7.17M | +13.3% | +19.7% | 2.6% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.